Regional · European Union

Cross-border purchase rules within the EU

Regional › European Union personal import formulary cost per milligram EMA

h.mbekiTL2 Moderator10 Aug 2025#1

On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion.

A coverage question with the paperwork detail included, since that is what determines the answer.

Denial received, with a stated reason. My reading of the reason is that it tells me exactly what to submit next, which is the useful thing about a well-written denial.

Before I spend a week on it: is my reading of the stated criterion correct, and is there a documented precedent for this specific ground?

37 likes 12mo

erratum_fileTL3Regular16 Aug 2025#2

I read the opening post twice before replying, because I had assumed the opposite.

Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules.

0 likes 11mo

v.kjaerTL2 Moderator20 Aug 2025#3

France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.

0 likes 11mo

GEldridgeTL3Regular24 Aug 2025#4

Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.

5 likes 11mo

z.adeyemiTL2 Moderator27 Aug 2025#5

v.kjaer, post #3: France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications. Go to post

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

27 likes in reply to #3 11mo

endpoint_lineTL330 Aug 2025#6

Collapsed as off-topic by two members at trust level 3 or above

Coming back to post #4, because the follow-up matters more than the original answer.

Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.

i.grimaldiTL2 Moderator2 Sep 2025#7

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

2 likes 11mo

RidgewayTL3Regular5 Sep 2025#8

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

8 likes 11mo

ca.vermeulenTL2 Moderator8 Sep 2025#9

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

9 likes 11mo

WoodhouseTL2Member11 Sep 2025 · edited#10

Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.

21 likes 11mo

KnowltonTL3Regular13 Sep 2025#11

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

15 likes 10mo

i.brobergTL2 Moderator16 Sep 2025 · edited#12

GEldridge, post #4: Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it. Go to post

post #11 is right about the mechanism and I think understates the practical bit.

Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.

6 likes in reply to #4 10mo

p.silvaTL2 Moderator19 Sep 2025#13

I read post #11 twice before replying, because I had assumed the opposite.

0 likes 10mo

e.kimaniTL2 Moderator21 Sep 2025#14

30 likes 10mo

a.weissTL224 Sep 2025#15

Collapsed as off-topic by two members at trust level 3 or above

On post #11 — agreed on the reasoning, with one qualification.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

a.almeidaTL2 Moderator26 Sep 2025#16

endpoint_line, post #6: Coming back to post #4, because the follow-up matters more than the original answer. Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common. Go to post

post #15 answers the question as asked. The question underneath it is different.

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

3 likes in reply to #6 10mo

l.dziedzicTL2 Moderator29 Sep 2025#17

h.mbeki, post #1: On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what determines the answer. Denial received, with a stated reason. My reading of the reason is that it tells me exactly what to submit next, which is the… Go to post

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

0 likes in reply to #1 10mo

k.roosTL2 Moderator1 Oct 2025#18

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

23 likes 10mo

e.mikkelsenTL2Member3 Oct 2025 · edited#19

Worth separating two things that post #15 runs together.

6 likes 10mo

z.nakamuraTL2 Moderator6 Oct 2025#20

1 like 10mo

LundqvistTL2Member8 Oct 2025#21

9 likes 10mo

s.hartmannTL2 Moderator10 Oct 2025#22

21 likes 10mo

KForsbergTL2Member12 Oct 2025#23

i.grimaldi, post #7: Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation. Go to post

Picking up post #20: that is the part I would want checked first.

Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.

0 likes in reply to #7 9mo

k.kimaniTL2 Moderator15 Oct 2025#24

p.silva, post #13: I read post #11 twice before replying, because I had assumed the opposite. Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules. Go to post

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

1 like in reply to #13 9mo

f.fenwickTL3Regular17 Oct 2025#25

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

14 likes 9mo

k.chukwuTL2 Moderator19 Oct 2025#26

29 likes 9mo

r.friskTL2 Moderator21 Oct 2025 · edited#27

This follows post #24 rather than contradicting it.

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

0 likes 9mo

h.ferrariTL2 Moderator23 Oct 2025#28

i.broberg, post #12: post #11 is right about the mechanism and I think understates the practical bit. Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters. Go to post

I read post #26 twice before replying, because I had assumed the opposite.

Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.

2 likes in reply to #12 9mo

e.lehtinenTL2 Moderator26 Oct 2025#29

e.mikkelsen, post #19: Worth separating two things that post #15 runs together. France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications. Go to post

post #28 answers the question as asked. The question underneath it is different.

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

3 likes in reply to #19 9mo

b.aaltoTL2 Moderator28 Oct 2025#30

On post #26 — agreed on the reasoning, with one qualification.

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

10 likes 9mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →